HBV Mutation Detail Information

> M213I Search Result

Mutation Information

Mutation Site	M213I
Mutation Type	Amino acid level
Gene/Protein/Region Type	S
Genotype/Subtype	B
Relevant Drug	lamivudine (LAM)
Country	China

Literature Information

PubMed PMID	12727536
Disease	Chronic hepatitis B
Published Year	2003
Journal	Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
Title	Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.
Author	Ayres A,Bartholomeusz A,Lau G,Lam KC,Lee JY,Locarnini S
Evidence	Subsequent to the instigation of antiviral therapy, the dominant drug resistant HBV which caused virological breakthrough and was associated with hepatic failure displayed a series of unique mutations particularly in the BCP (A1762T and G1764A) and in the polymerase (rtL180M, rtM204V, rtA222T and rtL336V), core (cP5T, cS26A, cV85I and cP135A), surface (sI195M and sM213I) and X (xK95Q, xN118T, xK130M and xV131I) proteins.

Contents
Description

Mutation Information Note

Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)

Literature Information Note

Evidence: sentence contains this mutation information in the citation